Gastroenterologie
a hepatologie

Current problems in the care of patients with inflammatory bowel disease in the Czech Republic

Martin Bortlík¹, Petra Matějková², Gleb Donin³

+ Affiliation
¹ Gastroenterologické oddělení, Nemocnice České Budějovice, a.s.
² ResTrial GastroEndo s.r.o., Praha
³ Katedra biomedicínské techniky, Fakulta biomedicínského inženýrství ČVUT v Praze

Summary

Inflammatory bowel disease poses a significant health, social and economic problem. A modern advanced therapy of IBD is effective and safe, and, simultaneously, reduces patients‘ disability together with indirect costs. The access to advanced therapy in Czech Republic is, however, a half of what we need in the real clinical practice. To improve this, we have to analyze both direct and indirect costs, increase budgets for advanced therapy and improve communication between the key stakeholders within the health and social system.

Keywords

ulcerative colitis, inflammatory bowel disease, Crohn’s disease, direct cost, indirect costs, invalidity

To read this article in full, please register for free on this website.

Benefits for subscribers

Benefits for logged users

Literature

1. Meima-van Praag EM, Buskens CJ, Hompes R et al. Surgical management of Crohn’s disease: a state of the art review. Int J Colorectal Dis 2021; 36(6): 1133–1145. doi: 10.1007/s00 384-021-03 857-2.
2. Burisch J, Zhao M, Odes S et al. The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol Hepatol 2023; 8(5): 458–492. doi: 10.1016/S2468-1253(23)00003-1.
3. Dušek L, Benešová L, Ngo O et al. Epidemiologie idiopatických střevních zánětů v české populaci – časový vývoj a statistické predikce počtu pacientů. Gastroent Hepatol 2019; 73(3): 257–264. doi: 10.14735/amgh2019257.
4. Burisch J, Vardi H, Schwartz D et al. Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: a population-based study. Lancet Gastroenterol Hepatol 2020; 5(5): 454–464. doi: 10.1016/S2468-1253(20)30012-1.
5. Dušek L. Predikce vývoje počtu pacientů a nákladů v segmentu centrové léčby – idiopatické střevní záněty. Přednáška. Biologická léčba IBD a pokroky v chirurgické léčbě IBD, Hotel Duo, Praha, září 2023.
6. Bhat S, Click B, Requeiro M. Safety and monitoring of inflammatory bowel disease advanced therapies. Inflamm Bowel Dis 2024; 30(5): 829–843. doi: 10.1093/ibd/izad120.
7. Noor NM, Lee JC, Bond S et al. A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn‘s disease (PROFILE): a multicentre, open-label randomised controlled trial. Lancet Gastroenterol Hepatol 2024; 9(5): 415–427. doi: 10.1016/S2468-1253(24)00034-7.
8. Burisch J, Kiudelis G, Kupcinskas L et al. Natural disease course of Crohn‘s disease during the first 5 years after diagnosis in a European population-based inception cohort: an Epi-IBD study. Gut 2019; 68(3): 423–433. doi: 10.1136/gutjnl-2017-315568.
9. Burisch J, Katsanos KH, Christodoulou DK et al. Natural disease course of ulcerative colitis during the first five years of follow-up in a European population-based inception cohort-an epi-IBD study. J Crohns Colitis 2019; 13(2): 198–208. doi: 10.1093/ecco-jcc/jjy154.
10. Český registr IBD pacientů na biologické terapii. 2025 [online]. Dostupné z: https: //credit.registry.cz/index.php.
11. Gómez-Labrador C, Ricart E, Iborra M et al. Trends in targeted therapy usage in inflammatory bowel disease: TRENDY study of ENEIDA. Pharmaceutics 2024; 16(5): 629. doi: 10.3390/ pharmaceutics16050629.
12. Donin G. Analýzy cest pacientů ve vybraných klinických oblastech. 2024 [online]. Dostupné z: https: //drg.uzis.cz/res/file/konference-cz-drg-2024/26-donin.pdf.
13. Bortlík M. Doporučení pro diagnostiku a léčbu Crohnovy choroby. Přednáška. 17. vzdělávací a diskusní gastroenterologické dny, Karlovy Vary, 2. 12. 2022.
14. Gordon H, Minozzi S, Kopylov U et al. ECCO guidelines on therapeutics in Crohn‘s disease: medical treatment. J Crohns Colitis 2024; 18(10): 1531–1555. doi: 10.1093/ecco-jcc/jjae091.
15. Feuerstein JD, Ho EY, Shmidt E et al. AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn‘s disease. Gastroenterology 2021; 160(7): 2496–2508. doi: 10.1053/ j.gastro.2021.04.022.
16. Büsch K, da Silva SA, Holton M et al. Sick leave and disability pension in inflammatory bowel disease: a systematic review. J Crohns Colitis 2014; 8(11): 1362–1377. doi: 10.1016/ j.crohns.2014.06.006.
17. Turner D, Ricciuto A, Lewis A et al. STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology 2021; 160(5): 1570–1583. doi: 10.1053/j.gastro.2020.12.031.
18. Ďuricová D, Pfeiferová M, Bortlík M et al. Kvalita života pacientů s idiopatickými střevními záněty v České republice – multicentrická studie. Gastroent Hepatol 2018; 72(1): 11–19. doi: 10.14735/amgh201811.
19. Decker B, Tuzil J, Lukas M et al. Patient-reported symptoms are a more reliable predictor of the societal burden compared to established physician-reported activity indices in inflammatory bowel disease: a cross-sectional study. Expert Rev Gastroenterol Hepatol 2023; 17(1): 99–108. doi: 10.1080/17474124.2023.21 61047.
20. Matějková P, Vítková Z. Idiopatické střevní záněty v posudkovém lékařství. Gastroent Hepatol 2019; 73(1): 37–42. doi: 10.14735/amgh 201937.